Patient Experience Star Ratings

At Mount Sinai, our mission is to provide exceptional patient care. To help patients feel more confident about their choice of doctors, we provide patient experience star ratings based on information collected by an independent organization, Press Ganey, which surveys hundreds of thousands of our patients every year. We hope this information will help you choose the doctor that is right for you.

What is the “Patient Experience Star Rating?”The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai physician communicated with them during an office visit. The Star Rating is based on patient responses to three questions on the Clinician & Group CAHPS (CG-CAHPS) Survey, a standardized questionnaire developed for use by Medicare:

During this visit, did this provider explain things in a way that was easy to understand?

During this visit, did this provider listen carefully to you?

Would you recommend this provider’s office to your family and friends?

Who receives a CG-CAHPS patient survey?Patients are randomly selected to receive a survey, either via mail or email, in which they are asked to provide feedback about their experience. That feedback is shared with physicians and medical practice leaders to help us improve and to recognize exceptional physicians.

Payment Methods

Dr. Alice Levine has
been a faculty member of the Mount Sinai School of Medicine since 1986 when she
completed her Fellowship in Endocrinology and Metabolism. She divides her
time between clinical, teaching and research activities. Her clinical
interests are diseases of the adrenal, pituitary and reproductive glands with
an emphasis on hormone-dependent neoplasias. She publishes extensively in these
fields. She is the Course Director for the Second Year Medical School
Endocrine Pathophysiology Course and is often cited as one of the outstanding
Faculty Teachers by Medical Students, Residents and Fellows. In her role
as Associate Program Director of the Research Track of the Internal Medicine
Residency and Research Director of the Endocrine Fellowship Program, she
mentors students, trainees and faculty in clinical and basic science research.

Language

Interactive roles of androgens and growth factors in human prostate development and neoplasia

Interactive roles of androgens and growth factors in human
prostate development and neoplasia

Dr. Levine’s Research
Laboratory focuses on understanding
how hormones and growth factors coordinately regulate prostate growth in order
to develop new treatment strategies for men with prostatic disorders.
Co-directed by Dr. Alexander Kirschenbaum, Clinical Associate Professor of
Urology, her group was the first to publish on the successful management of
benign prostatic hyperplasia with hormonal therapy. They also reported
that androgens increase stromal cell growth in the prostate and also regulate
the powerful angiogenic factor, vascular endothelial cell growth factor
(VEGF). Dr. Levine’s group were also among the first to determine the
cell-specific expression of cyclooxygenase-2 (COX-2) in the human prostate and
to report that selective COX-2 inhibitors kill prostate cancer cells in vitro
and in vivo. They established the role of COX-2 in hypoxia mediated
upregulation of survival and angiogenic proteins in human prostate cancer
cells. Dr. Levine’s group recently isolated and characterized a protein
derived from dietary bitter melon seeds that selectively kills pre-neoplastic
and neoplastic prostate cancer cells. Her group has also published
extensively on the mechanisms underlying prostate cancer bone metastases and
developed a bone-targeting compound aimed at preventing and treating prostate
cancer bone metastases.

The Patient Experience Rating is an average of all responses to care provider-related questions on our nationally recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5, with 5 being the best score.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr.Levine did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.